SCHEMBL18600201

SCHEMBL18600201

C#CCN(Cc1ccc(F)cc1)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 4/20 0.58
DHFR P00374 1/20 0.53
KCNQ4 P56696 4/20 0.47
KCNQ5 Q9NR82 3/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C8 P10632 1/20 0.46
CYP2B6 P20813 1/20 0.46
KCNQ2 O43526 1/20 0.45
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
MMP13 P45452 1/20 0.45
KCNJ1 P48048 1/20 0.44
KCNH2 Q12809 1/20 0.44
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
MEN1 O00255 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3737073 0.87 KCNJ1 (0.51) PYCR1MMP1MMP2MMP9MMP8
SCHEMBL15996915 0.79 PYCR1 (0.53) PYCR1DHFRKCNQ4KCNQ5CYP1A2
SCHEMBL18600540 0.77 KCNQ4 (0.48) PYCR1DHFRKCNQ4KCNQ5CYP1A2
SCHEMBL15996909 0.76 KCNQ2 (0.58) PYCR1DHFRKCNQ4KCNQ5CYP1A2
SCHEMBL15997126 0.76 KCNQ4 (0.53) PYCR1DHFRKCNQ4KCNQ5CYP1A2
SCHEMBL18600177 0.75 PYCR1 (0.45) PYCR1MMP1MMP2MMP9MMP8
SCHEMBL18600155 0.75 PYCR1 (0.53) PYCR1DHFRKCNQ4KCNQ5CYP1A2
SCHEMBL5682402 0.74 PYCR1 (1.00) PYCR1KCNH2CRHBPCRHR2MAOA
SCHEMBL3731833 0.73 CYP1A2 (0.52) PYCR1CYP1A2MEN1MAOAMAOB
SCHEMBL3153145 0.73 PYCR1 (0.62) PYCR1MMP1MMP2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180134677-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2018-05-17 US disclosed
US-20170081301-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONISTS, METHOD OF PREPARATION AND METHOD OF USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2017-03-23 US disclosed
US-20170081301-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONISTS, METHOD OF PREPARATION AND METHOD OF USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2017-03-23 US disclosed
EP-3138833-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2017-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134677-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF KCNQ5, KCNQ4, KCNQ1 PYCR1 2084/4885DHFR 2996/4885KCNQ4 2/4885
US-20170081301-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONISTS, METHOD OF PREPARATION AND METHOD OF USE THEREOF KCNQ5, KCNQ4, KCNQ3 PYCR1 2452/4885DHFR 2880/4885KCNQ4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.